Form 4: Syndax CFO Boosts Stake, Receives Equity Awards

Syndax Pharmaceuticals' CFO, Keith A. Goldan, increased his direct beneficial ownership through ESPP purchases and significant RSU and stock option grants, while also selling shares for tax obligations.

Summary

• Keith A. Goldan, Chief Financial Officer of Syndax Pharmaceuticals Inc (SNDX), reported multiple transactions in the company's common stock and derivative securities.
• Acquired 1,219 shares of Common Stock on January 30, 2026, through the Employee Stock Purchase Plan (ESPP) at a price of $8.48 per share.
• Received an award of 21,500 Restricted Stock Units (RSUs) on February 4, 2026, which will vest annually over three years, contingent on continued service.
• Received an award of 30,750 performance-based RSUs on February 4, 2026, with vesting contingent upon the achievement of pre-established performance metrics and continued service.
• Acquired 118,000 stock options on February 4, 2026, with an exercise price of $20.43, vesting monthly over a four-year period.
• Disposed of 2,082 shares of Common Stock on February 6, 2026, at $20.62 per share to cover tax withholding obligations related to RSU vesting.
• Following these transactions, Goldan directly beneficially owns 143,839 shares of Common Stock and 118,000 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to the significant equity awards granted to the CFO and his participation in the ESPP, which generally signals strong alignment of management's interests with long-term shareholder value. The tax-related sale is a routine event and does not detract significantly from the overall positive sentiment.

Positives

• The Chief Financial Officer acquired 1,219 shares through the Employee Stock Purchase Plan, indicating a direct investment and alignment with shareholder interests.
• Significant equity awards, including 21,500 time-based Restricted Stock Units and 30,750 performance-based Restricted Stock Units, were granted, aligning management incentives with long-term company performance.
• An award of 118,000 stock options further increases the CFO's vested interest in the company's future stock price appreciation.

Negatives

• The sale of 2,082 shares of Common Stock was executed to cover tax withholding obligations, which is a common practice but reduces direct beneficial ownership.

Future Outlook

The vesting schedules for the awarded Restricted Stock Units (RSUs) and stock options extend over three to four years, indicating a long-term incentive structure for the Chief Financial Officer. The performance-based RSUs are contingent on achieving pre-established company metrics.

Industry Context

StockSavvy.ai notes that insider transactions, particularly significant equity grants and purchases, are often viewed by the market as a signal of management's confidence in the company's future prospects and alignment with shareholder interests. The combination of ESPP purchases and substantial RSU/option awards for a CFO is a common practice in the biotechnology and pharmaceutical sectors to attract and retain key talent and incentivize long-term value creation.

Stakeholder Impact

• Shareholders: The increased equity ownership and long-term incentive awards for the CFO align his financial interests with those of shareholders, potentially fostering greater commitment to long-term value creation.
• Employees: The Employee Stock Purchase Plan (ESPP) participation indicates a benefit available to employees, promoting broader employee ownership and engagement.

Next Steps

• Vesting of 21,500 time-based RSUs annually over three years, commencing from February 4, 2026.
• Vesting of 30,750 performance-based RSUs upon achievement of pre-established performance metrics.
• Vesting of 118,000 stock options monthly over a four-year period, commencing from February 4, 2026.

Key Dates

Keywords

Syndax Pharmaceuticals, SNDX, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, CFO, Beneficial Ownership